Compare EGY & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | HELP |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | Canada |
| Employees | 281 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.4M | 712.2M |
| IPO Year | 1996 | 2020 |
| Metric | EGY | HELP |
|---|---|---|
| Price | $5.82 | $11.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.30 | ★ $51.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 05-07-2026 | 07-01-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $359,272,000.00 | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $29.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $3.76 |
| 52 Week High | $6.72 | $12.05 |
| Indicator | EGY | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 68.30 |
| Support Level | $5.02 | $4.41 |
| Resistance Level | $5.79 | N/A |
| Average True Range (ATR) | 0.18 | 0.80 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 81.14 | 87.44 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.